Dysplastic Nevi: Navigating the Risk Landscape

Scripps Health

B. Kelley

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

Sun Safety and Melanoma Awareness: Expert Tips on Preventing Sun Dam…

Oncology Data Advisor

T. Knight, M. Hadfield

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Vanderbilt University Medical Center (VUMC)

D. Johnson

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macro…

2024 ASCO® Annual Meeting Insights Hub

C. Blank

2024 Update on Melanoma, the Primary Lesion: Biopsy, Excision, and M…

Scripps Health

D. Kent

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Melanoma Research Foundation

S. Chandra

Overview of Adjuvant and Metastatic Landscape and Immunotherapy Toxc…

Ricky Frazer

Understanding Treatment Sequencing in Metastatic Melanoma: IO vs. Ta…

Vanderbilt University Medical Center (VUMC)

D. Johnson

Key Updates in Skin Melanoma

Total Health

R. Seedor

ASCO® 2024 Insights: "KEYNOTE-942 Trial - 3-Year Update on mRNA-4157…

2024 ASCO® Annual Meeting Insights Hub

J. Weber

Pediatric Melanoma

Penn Medicine Abramson Cancer Center

M. Jen